The effectiveness of bevacizumab therapy for macular edema due to central and branch retinal vein occlusions in a real world clinical practice: 12 month results

Poster Details

First Author: S.Parreira PORTUGAL

Co Author(s):    S. Barros   D. Lopes   A. Miranda   F. Freitas   A. Pereira   N. Campos              

Abstract Details


The aim of this study is to present the clinical outcomes of patients with macular edema secondary to central and branch retinal vein occlusions treated with intravitreal bevacizumab in a district general hospital.


Department of Ophthalmology, Hospital Garcia de Orta EPE, Almada, Portugal


Retrospective case notes analysis of patients with retinal vein occlusions treated with bevacizumab from January 2014 to January 2016. Demographic data, visual acuity (measured with Snellen and converted into LogMAR) and central macular thickness (CMT) calculated by spectral domain optical coherence tomography (SD OCT) were subjected to statistical analysis. Visual acuity and CMT were analysed at baseline, 4 weeks post-loading dose (3 consecutive injections, one per month) and at 1 year.


There were 28 and 46 patients with central and branch retinal vein occlusions, respectively. Baseline median visual acuity was 1 in both groups (interquartile range [IQR] 1 in the central and IQR 0.7 in the branch group). In both groups, visual improvement was statistically significant from baseline to post-loading dose (p=0.002 and p<0.001, respectively) and from baseline compared by month 12 (p=0.001 and p<0.001 respectively). In the branch group there was also statistically significant from post-loading dose compared by month 12 (p<0.001) but was not significant in the central group (p=0.116). Baseline median CMT was 500 μm (IQR 250) in the central group and 505 µm (IQR 217) in the branch group. The mean reduction in thickness was statistically significant at post-loading (p<0.001) and at the 12-month time point (p=0.001) for both groups. The median number of injections in 1 year was 5 in the central group and 4 in the branch group.


Retinal vein occlusion complicated by macular edema is accompanied by a significant decrement in visual acuity. Our results indicate that bevacizumab contributes to resolution of edema and stabilization of vision in the first year in the majority of the cases.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy